awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q28660580-D1603FD0-0A33-4B22-BE23-D673AD991801
Q28660580-D1603FD0-0A33-4B22-BE23-D673AD991801
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28660580-D1603FD0-0A33-4B22-BE23-D673AD991801
IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA
P2860
Q28660580-D1603FD0-0A33-4B22-BE23-D673AD991801
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28660580-D1603FD0-0A33-4B22-BE23-D673AD991801
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f61a9d5928734e4e8a0520d952d1c07cda2b72ae
P2860
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.